Medical equipments

Tender description

Please note this is not the start of a procurement process. A separate contract notice will be published to cover this requirement. Prior to commencing a formal procurement process and to help inform our strategy/ requirements, NHSBT is seeking to engage with suppliers of commercially available compact and fully automated molecular screening platform with blood borne virus assays. NHSBT would like to consult the market to improve our knowledge of all current platforms available in the market place, identify further opportunities and, potential issues, and gauge market interest in the proposed service. The equipment will be with minimal user operation and the technology will meet the current and future needs of the service, in a cost effective manner. Minimum requirements to be fulfilled: — fully inclusive, end to end system, extraction, amplification, detection, analysis and reporting — triplex assay for HBV, HCV and HIV nucleic acids — must have assays for WNV RNA and HEV RNA currently available — should have either the ability to modify in-house assays for use on the system or have other blood screening assays available (eg. Zika, Dengue and Chikungunya viruses) — all assays must be validated for donor/donation screening and on samples collected both pre- and post-mortem — all samples must be suitable for testing on the system without any pre-dilution or other pre-processing of the sample — total bench footprint of 2 m².